leadf
logo-loader
viewPharmaxis Ltd

Pharmaxis enrols first patient in its bone marrow cancer trial

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips discusses with Proactive's Andrew Scott the news they've enrolled the first patient in a clinical trial studying a potential new treatment for the bone marrow cancer myelofibrosis. The trial aims to demonstrate that PXS‐5505, the lead asset in Pharmaxis’ drug discovery pipeline, is safe and effective as a monotherapy in myelofibrosis patients, who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.

Quick facts: Pharmaxis Ltd

Price: 0.084 AUD

ASX:PXS
Market: ASX
Market Cap: $33.37 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pharmaxis Ltd named herein, including the promotion by the Company of Pharmaxis Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Pharmaxis begins exporting its cystic fibrosis drug Bronchitol® to the USA

Pharmaxis Ltd's (ASX:PXS) (OTCMKTS:PXSLY) (FRA:UUD) Gary Phillips speaks to Proactive's Andrew Scott following the news it has exported the first shipment of its locally developed and manufactured drug Bronchitol® to the USA. Phillips describes it as a proud and very rare achievement for a home‐...

2 weeks, 3 days ago

2 min read